Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide
Background: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). Asymmetric dimethylarginine (ADMA) has been associated with cardiovascular events in SLE patients and is a strong predictor of the progression of chronic kidney disease. However, whether...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-07-01
|
Series: | Kidney Diseases |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/509767 |
id |
doaj-1ea1adcbacb341658518539090a7b382 |
---|---|
record_format |
Article |
spelling |
doaj-1ea1adcbacb341658518539090a7b3822020-11-25T03:51:45ZengKarger PublishersKidney Diseases2296-93812296-93572020-07-016535536310.1159/000509767509767Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with CyclophosphamideLi ZhangKaichong ZhangWei DongRuizhao LiRenwei HuangHong ZhangWanxin ShiShuangxin LiuZhuo LiYuanhan ChenZhiming YeXinling LiangXueqing YuBackground: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). Asymmetric dimethylarginine (ADMA) has been associated with cardiovascular events in SLE patients and is a strong predictor of the progression of chronic kidney disease. However, whether ADMA can provide a predictive value for the diagnosis and treatment of LN patients remains unclear. This study evaluated the clinical significance of ADMA in LN patients. Methods: Blood samples of 114 patients with LN, 52 patients with primary glomerular disease, and 20 healthy people were collected. Plasma ADMA was measured via enzyme-linked immunosorbent assay. The relationship between plasma ADMA levels and pathological types and renal function and efficacy in LN patients were further analyzed. Results: There was no significant difference in plasma ADMA levels between LN and primary glomerular disease, but both were significantly higher than the values in healthy people (p < 0.05). Plasma ADMA levels in LN patients were negatively correlated with baseline estimated glomerular filtration rate (eGFR) and serum superoxide dismutase and positively correlated with serum cystatin C and serum β2-microglobulin (p < 0.05). The plasma ADMA levels of diffuse proliferative LN patients were significantly higher than those of other histopathological classes of LN. High plasma ADMA levels in LN patients (OR = 1.012; 95% CI 1.003–1.022; p = 0.010) is a risk factor for diffuse proliferative LN. The area under the receiver operating characteristic (ROC) curve of diagnosing diffuse proliferative LN by plasma ADMA was 0.707 (95% CI 0.610–0.805). The area under the ROC curve of combination with plasma ADMA, serum complement C3, and eGFR for diffuse proliferative LN was 0.796 (95% CI 0.713–0.879), which was significantly higher than that of ADMA, complement C3, and eGFR for diffuse proliferative LN alone, respectively (p < 0.05). Low plasma ADMA is an independent protective factor for proliferative LN patients achieving complete remission with cyclophosphamide as induction therapy (OR = 0.978; 95% CI 0.961–0.996; p < 0.05). Conclusion: High plasma ADMA levels in combination with eGFR and complement C3 may be useful to diagnose diffuse proliferative LN. Low plasma ADMA may help to predict complete remission in proliferative LN patients treated with cyclophosphamide as induction therapy. Plasma ADMA may be a new biomarker to determine the pathological type of LN and predict the therapeutic effect.https://www.karger.com/Article/FullText/509767lupus nephritisasymmetric dimethylargininebiomarkercyclophosphamide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li Zhang Kaichong Zhang Wei Dong Ruizhao Li Renwei Huang Hong Zhang Wanxin Shi Shuangxin Liu Zhuo Li Yuanhan Chen Zhiming Ye Xinling Liang Xueqing Yu |
spellingShingle |
Li Zhang Kaichong Zhang Wei Dong Ruizhao Li Renwei Huang Hong Zhang Wanxin Shi Shuangxin Liu Zhuo Li Yuanhan Chen Zhiming Ye Xinling Liang Xueqing Yu Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide Kidney Diseases lupus nephritis asymmetric dimethylarginine biomarker cyclophosphamide |
author_facet |
Li Zhang Kaichong Zhang Wei Dong Ruizhao Li Renwei Huang Hong Zhang Wanxin Shi Shuangxin Liu Zhuo Li Yuanhan Chen Zhiming Ye Xinling Liang Xueqing Yu |
author_sort |
Li Zhang |
title |
Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide |
title_short |
Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide |
title_full |
Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide |
title_fullStr |
Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide |
title_full_unstemmed |
Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide |
title_sort |
raised plasma levels of asymmetric dimethylarginine are associated with pathological type and predict the therapeutic effect in lupus nephritis patients treated with cyclophosphamide |
publisher |
Karger Publishers |
series |
Kidney Diseases |
issn |
2296-9381 2296-9357 |
publishDate |
2020-07-01 |
description |
Background: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). Asymmetric dimethylarginine (ADMA) has been associated with cardiovascular events in SLE patients and is a strong predictor of the progression of chronic kidney disease. However, whether ADMA can provide a predictive value for the diagnosis and treatment of LN patients remains unclear. This study evaluated the clinical significance of ADMA in LN patients. Methods: Blood samples of 114 patients with LN, 52 patients with primary glomerular disease, and 20 healthy people were collected. Plasma ADMA was measured via enzyme-linked immunosorbent assay. The relationship between plasma ADMA levels and pathological types and renal function and efficacy in LN patients were further analyzed. Results: There was no significant difference in plasma ADMA levels between LN and primary glomerular disease, but both were significantly higher than the values in healthy people (p < 0.05). Plasma ADMA levels in LN patients were negatively correlated with baseline estimated glomerular filtration rate (eGFR) and serum superoxide dismutase and positively correlated with serum cystatin C and serum β2-microglobulin (p < 0.05). The plasma ADMA levels of diffuse proliferative LN patients were significantly higher than those of other histopathological classes of LN. High plasma ADMA levels in LN patients (OR = 1.012; 95% CI 1.003–1.022; p = 0.010) is a risk factor for diffuse proliferative LN. The area under the receiver operating characteristic (ROC) curve of diagnosing diffuse proliferative LN by plasma ADMA was 0.707 (95% CI 0.610–0.805). The area under the ROC curve of combination with plasma ADMA, serum complement C3, and eGFR for diffuse proliferative LN was 0.796 (95% CI 0.713–0.879), which was significantly higher than that of ADMA, complement C3, and eGFR for diffuse proliferative LN alone, respectively (p < 0.05). Low plasma ADMA is an independent protective factor for proliferative LN patients achieving complete remission with cyclophosphamide as induction therapy (OR = 0.978; 95% CI 0.961–0.996; p < 0.05). Conclusion: High plasma ADMA levels in combination with eGFR and complement C3 may be useful to diagnose diffuse proliferative LN. Low plasma ADMA may help to predict complete remission in proliferative LN patients treated with cyclophosphamide as induction therapy. Plasma ADMA may be a new biomarker to determine the pathological type of LN and predict the therapeutic effect. |
topic |
lupus nephritis asymmetric dimethylarginine biomarker cyclophosphamide |
url |
https://www.karger.com/Article/FullText/509767 |
work_keys_str_mv |
AT lizhang raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT kaichongzhang raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT weidong raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT ruizhaoli raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT renweihuang raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT hongzhang raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT wanxinshi raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT shuangxinliu raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT zhuoli raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT yuanhanchen raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT zhimingye raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT xinlingliang raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide AT xueqingyu raisedplasmalevelsofasymmetricdimethylarginineareassociatedwithpathologicaltypeandpredictthetherapeuticeffectinlupusnephritispatientstreatedwithcyclophosphamide |
_version_ |
1724485797047959552 |